Healthcare Roundup – Aurora Cannabis under pressure on proposed public offering, Canada OKs Becton, Dickinson rapid COVID-19 test

Published on: November 10, 2020
Author: Amy Liu

Aurora Cannabis under pressure on proposed public offering

Aurora Cannabis (NYSE:ACB) -13.3% AH, seeks to offer the company’s units at $7.50/unit for total gross proceeds of ~$125M; each unit consists of one share and one half of one common share purchase warrant.

Each warrant will be exercisable to acquire one common share of the company for a 40 months period, post the offer close date, at an exercise price of $9/warrant share.

Underwriters granted 30-day option to purchase additional 15% of the units.

Offer final terms have not yet been disclosed.

Proceeds to be used for funding growth opportunities, working capital and other general corporate purposes.

Canada OKs Becton, Dickinson rapid COVID-19 test then places big order

Health Canada approves Becton, Dickinson and Company’s (NYSE:BDX) rapid point-of-care SARS-CoV-2 antigen test for use on the BD Veritor Plus System.

The nod also includes an order for 7.6M assays through March 2021.

The test generates a result in about 15 minutes.

Trxade inks agreement with to promote and market Amazon’s storage lockers

Effective on November 3, 2020, Trxade (NASDAQ:MEDS) entered into a solution marketing program agreement with  Services, LLC to promote and market Amazon’s storage lockers, a secure, self-service kiosk and pick-up program.

The consumers can pick up Amazon packages at their convenience, to network of independent pharmacies in the United States.

Pursuant to the agreement the company is to be paid a sliding fee for each independent pharmacy they introduce to, and which enters into an agreement with, Amazon in connection with the Amazon Locker or the Amazon Hub Counter program, to be invoiced and paid on a quarterly basis.

The agreement has a one-year term, automatically renewable thereafter for successive one-year terms if not terminated by either party with at least 30 days written notice prior to such automatic renewal date.

Black Diamond Therapeutics EPS beats by $0.02

Black Diamond Therapeutics (NASDAQ:BDTX): Q3 GAAP EPS of -$0.50 beats by $0.02.

Cash, cash equivalents and investments of $333.1M.

Cabaletta Bio EPS beats by $0.08

Cabaletta Bio (NASDAQ:CABA): Q3 GAAP EPS of -$0.36 beats by $0.08.

Cash and cash equivalents and investments of $118.1M.

Biotechnology Cannabis Healthcare Services Life Science